A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial

By sjmartinez • June 22, 2024

McKetin R, Degan TJ, Saunders L, Nguyen L, Dore G, Shoptaw S, Farrell M, Degenhardt L, Kelly PJ, Turner A, Clare PJ, Dean OM, Arunogiri S, Colledge-Frisby S, Koeijers J, Goodman-Meza D, Sinclair B, Reid D, Hill H, Hayllar J, Christmass M, Cordaro F, Lundin R, Liaw W, Liu D, Holyoak E, Wu BT, Keygan J, Kontogiannis A, Palmer L, Morrison C, Wrobel A, Hyland B, Byrne M, Russell S, Zahra E, Berk M. A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial. Trials. 2024 Jun 22;25(1):408. doi: 10.1186/s13063-024-08238-y. PMID: 38907288; PMCID: PMC11193254.

Tags: Addiction, Clinical Trial, depression, Infectious Diseases, Methamphetamine, Mirtazapine, pharmacotherapy, Psychiatry, Publications, sleep, substance use disorders, Treatment

Multiplex pan-filovirus assay performance and reproducibility across varied geographical and resource settings

Smith OA, Merritt S, Kompany JP, Hoff NA, Wong TAS, Kamara V, Tambu M, Halbrook M, Kindrachuk J, Barrall AL, Musene K, Martin SA, Berestecky[...]

Virus reactivation in acute and long COVID-19

Maguire C, Chen J, Rouphael N, Morse BA, Hoch A, Pickering H, Phan HV, Glascock A, Chu V, Dandekar R; IMPACC Network; Corry D, Kheradmand[...]

Variation in Hospital Visiting Hour Policies in Acute Care Facilities in Four U.S. States: An Exploratory Cross-Sectional Analysis

Garcia CY, Chou C, Caso E, Hudspeth JC, Allan-Blitz LT. Variation in Hospital Visiting Hour Policies in Acute Care Facilities in Four U.S. States: An[...]